RU2415677C2 - Композиция, содержащая вирусоподобную частицу (впч) и пептид амилоид-бета - Google Patents
Композиция, содержащая вирусоподобную частицу (впч) и пептид амилоид-бета Download PDFInfo
- Publication number
- RU2415677C2 RU2415677C2 RU2007120689/15A RU2007120689A RU2415677C2 RU 2415677 C2 RU2415677 C2 RU 2415677C2 RU 2007120689/15 A RU2007120689/15 A RU 2007120689/15A RU 2007120689 A RU2007120689 A RU 2007120689A RU 2415677 C2 RU2415677 C2 RU 2415677C2
- Authority
- RU
- Russia
- Prior art keywords
- dementia
- peptide
- weeks
- fragment
- design
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010012289 Dementia Diseases 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 238000013461 design Methods 0.000 claims description 36
- 229960004640 memantine Drugs 0.000 claims description 7
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims description 6
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 claims description 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 6
- 229960000744 vinpocetine Drugs 0.000 claims description 6
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 claims description 5
- 229960003642 nicergoline Drugs 0.000 claims description 5
- 239000002664 nootropic agent Substances 0.000 claims description 5
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004986 pyritinol Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000001777 nootropic effect Effects 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 241001515965 unidentified phage Species 0.000 claims description 4
- 241001534160 Escherichia virus Qbeta Species 0.000 claims description 3
- -1 calcium antagonists Substances 0.000 claims description 3
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229960004526 piracetam Drugs 0.000 claims description 3
- 238000001338 self-assembly Methods 0.000 claims description 3
- 229960002726 vincamine Drugs 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003776 glatiramer acetate Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 210000004558 lewy body Anatomy 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001534 risperidone Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
- 229960003946 selegiline Drugs 0.000 claims description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 21
- 229940068196 placebo Drugs 0.000 description 21
- 230000002354 daily effect Effects 0.000 description 15
- 238000010254 subcutaneous injection Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 4
- 229960000876 cinnarizine Drugs 0.000 description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229960004136 rivastigmine Drugs 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229960003135 donepezil hydrochloride Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229960000715 nimodipine Drugs 0.000 description 3
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960002024 galantamine hydrobromide Drugs 0.000 description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- 230000007570 microbleeding Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
- VFEKMAOUJHONFD-UHFFFAOYSA-N 5-[[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyldisulfanyl]methyl]-4-(hydroxymethyl)-2-methylpyridin-3-ol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO VFEKMAOUJHONFD-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Natural products O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229940072101 nimotop Drugs 0.000 description 1
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000000162 simple eye Anatomy 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0424563A GB0424563D0 (en) | 2004-11-05 | 2004-11-05 | Organic compounds |
| GB0424563.5 | 2004-11-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007120689A RU2007120689A (ru) | 2008-12-20 |
| RU2415677C2 true RU2415677C2 (ru) | 2011-04-10 |
Family
ID=33523293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007120689/15A RU2415677C2 (ru) | 2004-11-05 | 2005-11-03 | Композиция, содержащая вирусоподобную частицу (впч) и пептид амилоид-бета |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7867499B2 (enExample) |
| EP (2) | EP1812050A1 (enExample) |
| JP (2) | JP2008515954A (enExample) |
| KR (1) | KR20070073882A (enExample) |
| CN (1) | CN101048174A (enExample) |
| AR (1) | AR054092A1 (enExample) |
| AU (2) | AU2005300692A1 (enExample) |
| BR (1) | BRPI0517682A (enExample) |
| CA (1) | CA2581300A1 (enExample) |
| EC (1) | ECSP077415A (enExample) |
| GB (1) | GB0424563D0 (enExample) |
| GT (1) | GT200500313A (enExample) |
| IL (1) | IL182692A (enExample) |
| MA (1) | MA29020B1 (enExample) |
| MX (1) | MX2007005430A (enExample) |
| MY (1) | MY148584A (enExample) |
| NO (1) | NO20072743L (enExample) |
| NZ (1) | NZ583688A (enExample) |
| PE (1) | PE20061047A1 (enExample) |
| RU (1) | RU2415677C2 (enExample) |
| SG (1) | SG170646A1 (enExample) |
| TN (1) | TNSN07166A1 (enExample) |
| TW (1) | TWI380825B (enExample) |
| WO (1) | WO2006048295A1 (enExample) |
| ZA (1) | ZA200702369B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| TW201618806A (zh) * | 2010-03-29 | 2016-06-01 | 諾華公司 | 有機化合物之組合物 |
| AU2020348947B2 (en) | 2019-09-16 | 2025-11-27 | Amgen Inc. | Method for external sterilization of drug delivery device |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002056907A2 (en) * | 2001-01-19 | 2002-07-25 | Cytos Biotechnology Ag | Molecular antigen array presenting amyloid beta |
| WO2004016282A1 (en) * | 2002-07-19 | 2004-02-26 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0038154B1 (en) | 1980-04-15 | 1983-09-21 | Beecham Group Plc | Allergens modified with polysarcosines |
| US5204096A (en) | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| BR8707471A (pt) | 1986-09-22 | 1988-09-13 | Univ Emory | Vacina e processo de preparacao |
| US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
| US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
| US5142726A (en) * | 1991-04-03 | 1992-09-01 | Mann Robert F | Adjustable bristle length toothbrush |
| GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| ZA934199B (en) | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
| US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| WO1994009155A1 (en) * | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| JPH08505625A (ja) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性ｔリンパ球応答の誘導 |
| US6180771B1 (en) | 1993-12-08 | 2001-01-30 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor |
| US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| JPH09202735A (ja) | 1996-01-25 | 1997-08-05 | Nof Corp | リポソーム型アレルギー治療薬 |
| US5786161A (en) | 1996-06-06 | 1998-07-28 | Miltenyi Biotec. Gmbh | Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity |
| SE9604815D0 (sv) | 1996-12-20 | 1996-12-20 | Pharmacia & Upjohn Ab | A metod of diagnosis |
| WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| AU743827B2 (en) | 1997-04-09 | 2002-02-07 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP2002511385A (ja) | 1997-12-03 | 2002-04-16 | ニューララブ リミテッド | アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法 |
| ES2207177T3 (es) | 1998-02-12 | 2004-05-16 | Apovia, Inc. | Proteinas nucleo de la hepatitis b estrategicamente modificas y sus derivados. |
| US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
| EP1123114B1 (en) | 1998-10-21 | 2005-12-28 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Virus-like particles for the induction of autoantibodies |
| US6380364B1 (en) | 1998-11-23 | 2002-04-30 | Loyola University Of Chicago | Chimeric biotin-binding papillomavirus protein |
| CN100534529C (zh) | 1998-11-30 | 2009-09-02 | 希托斯生物技术股份公司 | 抗原的有序分子呈递，制备及使用的方法 |
| IL143475A0 (en) | 1998-12-04 | 2002-04-21 | Biogen Inc | Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same |
| IL145025A0 (en) | 1999-02-25 | 2002-06-30 | Smithkline Beecham Biolog | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| WO2001053457A2 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
| US20030086938A1 (en) | 2000-02-21 | 2003-05-08 | Jensen Martin Roland | Novel methods for down-regulation of amyloid |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| US8519005B2 (en) * | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US20030219459A1 (en) | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
| EP2351770A1 (en) | 2002-07-17 | 2011-08-03 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| CN100518823C (zh) | 2002-07-18 | 2009-07-29 | 赛托斯生物技术公司 | 半抗原-载体偶联物及其用途 |
| US20040076645A1 (en) | 2002-07-19 | 2004-04-22 | Bachmann Martin F. | Ghrelin-carrier conjugates |
| AU2003254914A1 (en) | 2002-08-12 | 2004-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Amino acid-containing chewable |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
-
2004
- 2004-11-05 GB GB0424563A patent/GB0424563D0/en not_active Ceased
-
2005
- 2005-10-28 MY MYPI20055090A patent/MY148584A/en unknown
- 2005-10-28 GT GT200500313A patent/GT200500313A/es unknown
- 2005-11-03 US US11/718,665 patent/US7867499B2/en not_active Expired - Fee Related
- 2005-11-03 EP EP05801760A patent/EP1812050A1/en not_active Withdrawn
- 2005-11-03 CA CA002581300A patent/CA2581300A1/en not_active Abandoned
- 2005-11-03 EP EP20100177232 patent/EP2286830A3/en not_active Withdrawn
- 2005-11-03 BR BRPI0517682-4A patent/BRPI0517682A/pt not_active IP Right Cessation
- 2005-11-03 MX MX2007005430A patent/MX2007005430A/es active IP Right Grant
- 2005-11-03 AR ARP050104609A patent/AR054092A1/es unknown
- 2005-11-03 JP JP2007536128A patent/JP2008515954A/ja not_active Withdrawn
- 2005-11-03 SG SG200907306-5A patent/SG170646A1/en unknown
- 2005-11-03 CN CNA2005800368845A patent/CN101048174A/zh active Pending
- 2005-11-03 WO PCT/EP2005/011788 patent/WO2006048295A1/en not_active Ceased
- 2005-11-03 PE PE2005001290A patent/PE20061047A1/es not_active Application Discontinuation
- 2005-11-03 NZ NZ583688A patent/NZ583688A/en not_active IP Right Cessation
- 2005-11-03 AU AU2005300692A patent/AU2005300692A1/en not_active Abandoned
- 2005-11-03 RU RU2007120689/15A patent/RU2415677C2/ru not_active IP Right Cessation
- 2005-11-03 KR KR1020077010214A patent/KR20070073882A/ko not_active Ceased
- 2005-11-04 TW TW094138839A patent/TWI380825B/zh not_active IP Right Cessation
-
2007
- 2007-03-22 ZA ZA200702369A patent/ZA200702369B/xx unknown
- 2007-04-19 IL IL182692A patent/IL182692A/en not_active IP Right Cessation
- 2007-04-24 EC EC2007007415A patent/ECSP077415A/es unknown
- 2007-05-04 TN TNP2007000166A patent/TNSN07166A1/fr unknown
- 2007-05-14 MA MA29899A patent/MA29020B1/fr unknown
- 2007-05-30 NO NO20072743A patent/NO20072743L/no not_active Application Discontinuation
-
2010
- 2010-02-04 AU AU2010200410A patent/AU2010200410B2/en not_active Ceased
- 2010-12-17 US US12/971,534 patent/US8460676B2/en not_active Expired - Fee Related
-
2011
- 2011-05-02 JP JP2011102847A patent/JP2011157395A/ja active Pending
-
2013
- 2013-05-13 US US13/892,552 patent/US8617566B2/en not_active Expired - Fee Related
- 2013-11-20 US US14/085,048 patent/US20140079730A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002056907A2 (en) * | 2001-01-19 | 2002-07-25 | Cytos Biotechnology Ag | Molecular antigen array presenting amyloid beta |
| WO2004016282A1 (en) * | 2002-07-19 | 2004-02-26 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
Non-Patent Citations (1)
| Title |
|---|
| GOLDE ТЕ. Alzheimer disease therapy: can amyloid cascade be halted?// J. Clin. Invest. 2003, v.111, (1), pp.11-18. XU S. Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed В cell lines from patients with Alzheimer's disease, Mechanism of ageing and development, 1997, v.94, pp.213-222. GEYLIS V. et al. Human monoclonal antibodies against amyloid-beta from healthy adults// Neurobiol Aging, 2005, May, v.26 (5), pp.597-606. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2603486C2 (ru) | КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ АМИЛОИДНЫЙ ПЕПТИД Аβ-1-6, ПРИСОЕДИНЕННЫЙ К ВИРУСОПОДОБНОЙ ЧАСТИЦЕ И АДЪЮВАНТУ | |
| US20240148782A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| US11147873B2 (en) | Treatment of Alzheimer's Disease (AD) with an aluminum salt | |
| US8617566B2 (en) | Composition comprising VLP and amyloid beta peptide | |
| AU2015254663B2 (en) | Treatment and prevention of Alzheimer's Disease (AD) | |
| AU2011253800B2 (en) | Composition comprising VLP and amyloid-beta peptide | |
| HK1150961A (en) | Composition comprising vlp and amyloid-beta peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171104 |